OSE Immunotherapeutics - AbbVie deal clears antitrust hurdle
OSE has announced that its licence agreement with AbbVie has cleared antitrust review and has become effective. As previously noted, this is...
422 Views
OSE Immunotherapeutics - Funding accelerates Tedopi clinical development
Despite the challenging macroeconomic environment, OSE announced an encouraging funding win with the receipt of €8.4m in non-dilutive public...
451 Views
OSE Immunotherapeutics - Pipeline momentum builds into FY24
OSE Immunotherapeutics’ (OSE’s) FY23 update summarised an active period for its clinical pipeline that was capped by the post-period $713m deal...
255 Views
OSE Immunotherapeutics - One step closer to key data readouts
OSE Immunotherapeutics has announced the completion of patient enrolment in its Phase II CoTikiS trial, marking another step in the clinical...
191 Views
OSE Immunotherapeutics - Confidence boost with AbbVie partnership
OSE Immunotherapeutics has announced a global licence and collaboration agreement with AbbVie to develop OSE-230, a novel monoclonal antibody, for...
196 Views